Abstract
Background: Major depressive disorder (MDD) is associated with high mortality and morbidity rates, and currently, approximately 340 million people worldwide suffer from depression at some point in life. In view of the growing socio-economic and clinical impact, several studies have focused on the etiopathology of MDD, suggesting that not only the monoaminergic system but also other brain mechanisms may be involved in the pathophysiology of MDD. Recent studies have shown a link between inflammation and MDD and have also demonstrated that antidepressants and antiinflammatory drugs can act to reduce inflammation, thereby improving depressive symptoms. Animal models of depression are indispensable for studying the pathophysiology of this disorder and new treatments for it. Further, studies have shown that rodent models of depression are also associated with elevated levels of inflammation in the periphery and brain.
Objective: This review will highlight the role of immune inflammation in MDD and the significance of immune system modulators with antidepressant effects in the treatment of MDD, based on studies using animal models of depression.Keywords: Antidepressants, anti-inflammatory drugs, immune system, animal model of depression, major depressive disorder.
CNS & Neurological Disorders - Drug Targets
Title:Immune System Modulators with Antidepressant Effects: Evidence from Animal Models
Volume: 16 Issue: 4
Author(s): Helena M. Abelaira, Amanda L. Maciel, Joao Quevedo and Gislaine Z. Reus*
Affiliation:
- Laboratory of Neurosciences, University of Southern Santa Catarina, Criciúma, SC - 88806-000,Brazil
Keywords: Antidepressants, anti-inflammatory drugs, immune system, animal model of depression, major depressive disorder.
Abstract: Background: Major depressive disorder (MDD) is associated with high mortality and morbidity rates, and currently, approximately 340 million people worldwide suffer from depression at some point in life. In view of the growing socio-economic and clinical impact, several studies have focused on the etiopathology of MDD, suggesting that not only the monoaminergic system but also other brain mechanisms may be involved in the pathophysiology of MDD. Recent studies have shown a link between inflammation and MDD and have also demonstrated that antidepressants and antiinflammatory drugs can act to reduce inflammation, thereby improving depressive symptoms. Animal models of depression are indispensable for studying the pathophysiology of this disorder and new treatments for it. Further, studies have shown that rodent models of depression are also associated with elevated levels of inflammation in the periphery and brain.
Objective: This review will highlight the role of immune inflammation in MDD and the significance of immune system modulators with antidepressant effects in the treatment of MDD, based on studies using animal models of depression.Export Options
About this article
Cite this article as:
Abelaira M. Helena, Maciel L. Amanda, Quevedo Joao and Reus Z. Gislaine*, Immune System Modulators with Antidepressant Effects: Evidence from Animal Models, CNS & Neurological Disorders - Drug Targets 2017; 16 (4) . https://dx.doi.org/10.2174/1871527316666170404141620
DOI https://dx.doi.org/10.2174/1871527316666170404141620 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Novel Treatments in Subarachnoid Hemorrhage
The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Borderland and Borderline: Understanding and Treating Adolescent Migrants in Crisis
Adolescent Psychiatry Affective Risk for Problem Drinking: Reciprocal Influences Among Negative Urgency, Affective Lability, and Rumination
Current Drug Research Reviews Opinion Paper: A Cognitive-cultural Segregation and the Three Stages of Aging
Current Aging Science Current Status of Tyrosine Hydroxylase in Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Inflammation and Age-Related Iron Accumulation in F344 Rats
Current Aging Science Beta-Blockers in Children with Congenital Heart Disease Before a Corrective Procedure
Reviews on Recent Clinical Trials Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews Medicinal Chemistry of 2,2,4-Substituted Morpholines
Current Medicinal Chemistry Sodium Hydrosulfide Attenuates Beta-Amyloid-Induced Cognitive Deficits and Neuroinflammation via Modulation of MAPK/NF-κB Pathway in Rats
Current Alzheimer Research Editorial [Hot Topic: Therapeutic Use of Heat Shock Proteins and Essential Factors in Prognosis, Diagnosis and Treatment of Neurodegenerative and Metabolic Diseases (Guest Editor: Yusuf Tutar)]
Current Pharmaceutical Biotechnology Targeting CNS Transporters for Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Flavonoids and its Neuroprotective Effects on Brain Ischemia and Neurodegenerative Diseases
Current Drug Targets Advantages of Nanotechnology- Based Chinese Herb Drugs on Biological Activities
Current Drug Metabolism Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry Human Imprinting Anomalies in Fetal and Childhood Growth Disorders: Clinical Implications and Molecular Mechanisms
Current Pharmaceutical Design Adipose-Derived Stromal/Stem Cells (ASC) in Regenerative Medicine: Pharmaceutical Applications
Current Pharmaceutical Design Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Radical Scavenging and Antioxidant Capacity of Serotonin
Current Bioactive Compounds Cerebral Hypoperfusion During Carotid Artery Stenosis can Lead to Cognitive Deficits that may be Independent of White Matter Lesion Load
Current Neurovascular Research Why Do We Need New Gene Therapy Viral Vectors? Characteristics, Limitations and Future Perspectives of Viral Vector Transduction
Current Gene Therapy